Initiation of coverage | BIONTECH | Creating a one-stop-shop for cancer patients
BioNTech (BNTX) is an immuno-oncology company with a ‘full-spectrum’ of technologies to tackle cancer. Company’s mRNA-based platform serves as a foundation, upon which the company can build multiple treatment modalities, including cancer vaccines, RiboMABs and RiboCytokines. Albeit the company did not stop there and broadened its armamentarium with complementary platforms, including cell therapies, as well as bispecific antibodies and small molecules. Thus, in our view, BNTX willingness to go extra mile by combining different therapeutic approaches and essentially creating a ‘one stop shop’ for cancer patients truly differentiates it from other mRNA and immuno-oncology companies.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.